December 22, 2016Thrombosis and Haemostasis

Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

View Full Paper

Ask AI

Bookmark

Population

PT-VWD mouse model (hTgG233V mice)

Comparison

In vivo inhibition of GPIbα using 6B4 vs Control hTgWT mice

Design

Preclinical

Authors

HKHarmanpreet KaurLovely Professional University KCKathryn CorscaddenQueen's University JWJerry WareBoston University

Discussion

Member takes

Implication

Challenges historical clearance models in PT-VWD; leaves open GPIbα-targeted therapies pending human studies.

Structured PICO

Population

PT-VWD mouse model (hTgG233V mice)

Intervention

In vivo inhibition of GPIbα using 6B4 (a monoclonal antibody)

Comparator

Control hTgWT mice

Outcome

Platelet pro-coagulant capacity, whole blood platelet aggregation, and in vivo thrombus formation (laser injury model)surrogate

Platelets with hyper-responsive GPIbα exhibit complex intrinsic defects beyond previously described mechanisms, contributing to impaired in vivo thrombosis.

Cite This Study

Kaur et al. (2016) studied this question.

synapsesocial.com/papers/6a7104fb26a7f98052dd7469 https://doi.org/10.1160/th16-04-0317

View Full Paper

Ask AI

Bookmark

Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider